Cargando…

Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic

PURPOSE: Although denosumab is a safe and effective treatment for osteoporosis in various clinical trials, few studies have investigated its efficacy in specific clinical situations. The effect of non-compliance with the standard six-month dosing regimen for denosumab on bone mineral density (BMD) w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Chun-Feng, Shiao, Ming-Shi, Mao, Tso-Yen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289459/ https://www.ncbi.nlm.nih.gov/pubmed/34290494 http://dx.doi.org/10.2147/PPA.S316144

Ejemplares similares

The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review
por: Wong-Pack, Matthew, et al.
Publicado: (2016)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids
por: Sawamura, Masato, et al.
Publicado: (2017)

Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients
por: Jeong, Chaiho, et al.
Publicado: (2020)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

Retrospective Study of the Effects of Zoledronic Acid on Muscle Mass in Osteoporosis Patients
por: Huang, Chun-Feng, et al.
Publicado: (2021)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis
por: Stumpf, U., et al.
Publicado: (2021)

Bisphophonates in CKD Patients with Low Bone Mineral Density
por: Liu, Wen-Chih, et al.
Publicado: (2013)

The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients
por: Huang, Chun-Feng, et al.
Publicado: (2023)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study
por: Takami, Hiroya, et al.
Publicado: (2017)

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
por: Makras, Polyzois, et al.
Publicado: (2021)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
por: Kim, Seong-Kyu, et al.
Publicado: (2023)

Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment
por: Petranova, Tzvetanka, et al.
Publicado: (2014)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice
por: Boyanov, Mihail, et al.
Publicado: (2016)

SUN-396 Denosumab Preserves Bone Mineral Density at the Knee in Persons with Subacute Spinal Cord Injury
por: Bauman, William Alan, et al.
Publicado: (2020)

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
por: Yamaguchi, Yuta, et al.
Publicado: (2020)

Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine
por: Laroche, Michel, et al.
Publicado: (2023)

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
por: Suzuki, Takako, et al.
Publicado: (2017)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
por: Kang, Taewook, et al.
Publicado: (2022)

Can lumbar spine bone mineral density predict readmission in denosumab-treated patients with chronic kidney disease?
por: Cheng, Ben-Chung, et al.
Publicado: (2017)

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
por: Nakamura, Yukio, et al.
Publicado: (2018)

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
por: Ferrari, S, et al.
Publicado: (2019)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
por: Kendler, D.L., et al.
Publicado: (2019)

Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer
por: Sakaguchi, Koichi, et al.
Publicado: (2019)

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
por: McClung, M. R., et al.
Publicado: (2012)

Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change
por: Nakatoh, Shinichi
Publicado: (2017)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment
por: Razaq, Abdul, et al.
Publicado: (2019)

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis
por: Tsuchiya, Koki, et al.
Publicado: (2019)

The Effect of Denosumab in Elderly Patients Regarding Bone Density and Fracture Risk
por: Yoon, Sung-Hyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dk44pkv7lgfrq2hfeg588u1mt5